Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of severe visual loss and blindness over the age of 50 in developed countries. Vascular endothelial growth factor (VEGF) is considered as a critical molecule in the pathogenesis of choroidal neovascularization (CNV), which characterizes the...
Main Authors: | Ilias Zampros, Anna Praidou, Periklis Brazitikos, Panagiotis Ekonomidis, Sofia Androudi |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Journal of Ophthalmology |
Online Access: | http://dx.doi.org/10.1155/2012/319728 |
Similar Items
-
Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration
by: Tranos P, et al.
Published: (2013-06-01) -
Repeated intravitreal injections of antivascular endothelial growth factor in patients with neovascular age-related macular degeneration may increase the risk of ischemic optic neuropathy
by: Yu-Yen Chen, et al.
Published: (2019-12-01) -
Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study
by: Benjamin Chi-Lan Yang, et al.
Published: (2019-01-01) -
Effects of Smoking on Outcomes of Antivascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration Smoking and Anti-VEGF Therapy in nAMD
by: Hiroyuki Kamao, et al.
Published: (2018-01-01) -
Comparing vision and macular thickness in neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion patients treated with intravitreal antivascular endothelial growth factor injections in clinical practice
by: Rajya L Gurung, et al.
Published: (2021-07-01)